Panos Roussos1, Pavel Katsel2, Peter Fam3, Weilun Tan2, Dushyant P Purohit4, Vahram Haroutunian5. 1. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Genetics and Genomic Science and Institute for Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Mental Illness Research, Education, and Clinical Center (VISN 3), James J. Peters VA Medical Center, Bronx, NY, USA. 2. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 3. Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 5. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Mental Illness Research, Education, and Clinical Center (VISN 3), James J. Peters VA Medical Center, Bronx, NY, USA; Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: vahram.haroutunian@mssm.edu.
Abstract
INTRODUCTION: The objective of this study was to elucidate the relationship between the triggering receptor expressed on myeloid cells 2 (TREM2) risk variant, neuropathological lesions, alterations in gene and protein expression, and the severity of neuroinflammation. METHODS: The genetic association study of the R47 H TREM2 variant with Alzheimer's disease (AD), neuropathology, and changes in TREM2 and TYRO protein tyrosine kinase-binding protein (TYROBP) gene and protein expression, and neuroinflammatory markers. RESULTS: The TREM2 variant is associated with: (i) AD (odds ratio: 4.76; P = .014); (ii) increased density of amyloid plaques and neurofibrillary tangles in multiple brain regions; (iii) increased TREM2 (P = .041) and TYROBP (P = .006) gene expression; (iv) decreased TREM2 protein levels (P = .016); and (v) upregulation of proinflammatory cytokines (regulated on activation, normal T cell expressed and secreted [RANTES] and interferon [IFN] gamma) (P = .003) and nominal downregulation of protective markers (α2-macroglobulin, interleukin 4 or IL-4, and ApoA1) (P = .018). DISCUSSION: These findings link the TREM2 missense mutation with specific molecular abnormalities and increases in neuropathological lesions in the human brain.
INTRODUCTION: The objective of this study was to elucidate the relationship between the triggering receptor expressed on myeloid cells 2 (TREM2) risk variant, neuropathological lesions, alterations in gene and protein expression, and the severity of neuroinflammation. METHODS: The genetic association study of the R47 H TREM2 variant with Alzheimer's disease (AD), neuropathology, and changes in TREM2 and TYRO protein tyrosine kinase-binding protein (TYROBP) gene and protein expression, and neuroinflammatory markers. RESULTS: The TREM2 variant is associated with: (i) AD (odds ratio: 4.76; P = .014); (ii) increased density of amyloid plaques and neurofibrillary tangles in multiple brain regions; (iii) increased TREM2 (P = .041) and TYROBP (P = .006) gene expression; (iv) decreased TREM2 protein levels (P = .016); and (v) upregulation of proinflammatory cytokines (regulated on activation, normal T cell expressed and secreted [RANTES] and interferon [IFN] gamma) (P = .003) and nominal downregulation of protective markers (α2-macroglobulin, interleukin 4 or IL-4, and ApoA1) (P = .018). DISCUSSION: These findings link the TREM2 missense mutation with specific molecular abnormalities and increases in neuropathological lesions in the human brain.
Authors: Gernot Kleinberger; Yoshinori Yamanishi; Marc Suárez-Calvet; Eva Czirr; Ebba Lohmann; Elise Cuyvers; Hanne Struyfs; Nadine Pettkus; Andrea Wenninger-Weinzierl; Fargol Mazaheri; Sabina Tahirovic; Alberto Lleó; Daniel Alcolea; Juan Fortea; Michael Willem; Sven Lammich; José L Molinuevo; Raquel Sánchez-Valle; Anna Antonell; Alfredo Ramirez; Michael T Heneka; Kristel Sleegers; Julie van der Zee; Jean-Jacques Martin; Sebastiaan Engelborghs; Asli Demirtas-Tatlidede; Henrik Zetterberg; Christine Van Broeckhoven; Hakan Gurvit; Tony Wyss-Coray; John Hardy; Marco Colonna; Christian Haass Journal: Sci Transl Med Date: 2014-07-02 Impact factor: 17.956
Authors: Thorlakur Jonsson; Jasvinder K Atwal; Stacy Steinberg; Jon Snaedal; Palmi V Jonsson; Sigurbjorn Bjornsson; Hreinn Stefansson; Patrick Sulem; Daniel Gudbjartsson; Janice Maloney; Kwame Hoyte; Amy Gustafson; Yichin Liu; Yanmei Lu; Tushar Bhangale; Robert R Graham; Johanna Huttenlocher; Gyda Bjornsdottir; Ole A Andreassen; Erik G Jönsson; Aarno Palotie; Timothy W Behrens; Olafur T Magnusson; Augustine Kong; Unnur Thorsteinsdottir; Ryan J Watts; Kari Stefansson Journal: Nature Date: 2012-08-02 Impact factor: 49.962
Authors: Jessica A Hamerman; Jessica R Jarjoura; Mary Beth Humphrey; Mary C Nakamura; William E Seaman; Lewis L Lanier Journal: J Immunol Date: 2006-08-15 Impact factor: 5.422
Authors: A Parachikova; M G Agadjanyan; D H Cribbs; M Blurton-Jones; V Perreau; J Rogers; T G Beach; C W Cotman Journal: Neurobiol Aging Date: 2006-10-18 Impact factor: 4.673
Authors: Thorlakur Jonsson; Hreinn Stefansson; Stacy Steinberg; Ingileif Jonsdottir; Palmi V Jonsson; Jon Snaedal; Sigurbjorn Bjornsson; Johanna Huttenlocher; Allan I Levey; James J Lah; Dan Rujescu; Harald Hampel; Ina Giegling; Ole A Andreassen; Knut Engedal; Ingun Ulstein; Srdjan Djurovic; Carla Ibrahim-Verbaas; Albert Hofman; M Arfan Ikram; Cornelia M van Duijn; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson Journal: N Engl J Med Date: 2012-11-14 Impact factor: 91.245
Authors: Rita Guerreiro; Aleksandra Wojtas; Jose Bras; Minerva Carrasquillo; Ekaterina Rogaeva; Elisa Majounie; Carlos Cruchaga; Celeste Sassi; John S K Kauwe; Steven Younkin; Lilinaz Hazrati; John Collinge; Jennifer Pocock; Tammaryn Lashley; Julie Williams; Jean-Charles Lambert; Philippe Amouyel; Alison Goate; Rosa Rademakers; Kevin Morgan; John Powell; Peter St George-Hyslop; Andrew Singleton; John Hardy Journal: N Engl J Med Date: 2012-11-14 Impact factor: 91.245
Authors: Marco A Meraz-Ríos; Danira Toral-Rios; Diana Franco-Bocanegra; Juana Villeda-Hernández; Victoria Campos-Peña Journal: Front Integr Neurosci Date: 2013-08-13
Authors: Boram Kim; EunRan Suh; Aivi T Nguyen; Stefan Prokop; Bailey Mikytuck; Olamide A Olatunji; John L Robinson; Murray Grossman; Jeffrey S Phillips; David J Irwin; Dawn Mechanic-Hamilton; David A Wolk; John Q Trojanowski; Corey T McMillan; Vivianna M Van Deerlin; Edward B Lee Journal: Acta Neuropathol Date: 2022-09-16 Impact factor: 15.887
Authors: Samantha L Rosenthal; Mikhil N Bamne; Xingbin Wang; Sarah Berman; Beth E Snitz; William E Klunk; Robert A Sweet; F Yesim Demirci; Oscar L Lopez; M Ilyas Kamboh Journal: Neurobiol Aging Date: 2015-04-25 Impact factor: 4.673
Authors: Maya Koronyo-Hamaoui; Julia Sheyn; Eric Y Hayden; Songlin Li; Dieu-Trang Fuchs; Giovanna C Regis; Dahabada H J Lopes; Keith L Black; Kenneth E Bernstein; David B Teplow; Sebastien Fuchs; Yosef Koronyo; Altan Rentsendorj Journal: Brain Date: 2020-01-01 Impact factor: 13.501
Authors: Aleksandar Obradovic; Nivedita Chowdhury; Scott M Haake; Casey Ager; Vinson Wang; Lukas Vlahos; Xinzheng V Guo; David H Aggen; W Kimryn Rathmell; Eric Jonasch; Joyce E Johnson; Marc Roth; Kathryn E Beckermann; Brian I Rini; James McKiernan; Andrea Califano; Charles G Drake Journal: Cell Date: 2021-05-20 Impact factor: 66.850